Mingyang Song1, Reiko Nishihara1, Kana Wu1, Zhi Rong Qian1, Sun A Kim1, Yasutaka Sukawa1, Kosuke Mima1, Kentaro Inamura1, Atsuhiro Masuda1, Juhong Yang1, Charles S Fuchs1, Edward L Giovannucci1, Shuji Ogino1, Andrew T Chan1. 1. Department of Nutrition (MS, RN, KW, ELG) and Department of Epidemiology (MS, ELG, SO), Harvard School of Public Health, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (RN, ZRQ, SAK, YS, KM, AM, JY, CSF, SO); Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD (KI); Channing Division of Network Medicine, Department of Medicine (CSF, ELG, SO, ATC) and Department of Pathology (SO), Harvard Medical School, Brigham and Women's Hospital, Boston, MA; Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA (ATC).
Abstract
BACKGROUND: Chronic inflammation is involved in the development of colorectal cancer (CRC) and microsatellite instability (MSI), a distinct phenotype of CRC. Experimental evidence indicates an anti-inflammatory and antineoplastic effect of marine ω-3 polyunsaturated fatty acids (PUFAs). However, epidemiologic data remain inconclusive. METHODS: We investigated whether the association between marine ω-3 PUFAs and CRC varies by MSI-defined subtypes of tumors in the Nurses' Health Study and Health Professionals Follow-up Study. We documented and classified 1125 CRC cases into either MSI-high tumors, in which 30% or more of the 10 microsatellite markers demonstrated instability, or microsatellite-stable (MSS) tumors. Cox proportional hazards model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of MSS tumors and MSI-high tumors in relation to marine ω-3 PUFA intake. All statistical tests were two-sided. RESULTS: Marine ω-3 PUFA intake was not associated with overall incidence of CRC. However, a statistically significant difference was detected by MSI status (P heterogeneity = .02): High marine ω-3 PUFA intake was associated with a lower risk of MSI-high tumors (comparing ≥0.30g/d with <0.10g/d: multivariable HR = 0.54, 95% CI = 0.35 to 0.83, P linearity = .03) but not MSS tumors (HR = 0.97, 95% CI = 0.78 to 1.20, P linearity = .28). This differential association appeared to be independent of CpG island methylator phenotype and BRAF mutation status. CONCLUSIONS: High marine ω-3 PUFA intake is associated with lower risk of MSI-high CRC but not MSS tumors, suggesting a potential role of ω-3 PUFAs in protection against CRC through DNA mismatch repair. Further research is needed to confirm our findings and elucidate potential underlying mechanisms.
BACKGROUND:Chronic inflammation is involved in the development of colorectal cancer (CRC) and microsatellite instability (MSI), a distinct phenotype of CRC. Experimental evidence indicates an anti-inflammatory and antineoplastic effect of marine ω-3 polyunsaturated fatty acids (PUFAs). However, epidemiologic data remain inconclusive. METHODS: We investigated whether the association between marine ω-3 PUFAs and CRC varies by MSI-defined subtypes of tumors in the Nurses' Health Study and Health Professionals Follow-up Study. We documented and classified 1125 CRC cases into either MSI-high tumors, in which 30% or more of the 10 microsatellite markers demonstrated instability, or microsatellite-stable (MSS) tumors. Cox proportional hazards model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of MSS tumors and MSI-high tumors in relation to marine ω-3 PUFA intake. All statistical tests were two-sided. RESULTS: Marine ω-3 PUFA intake was not associated with overall incidence of CRC. However, a statistically significant difference was detected by MSI status (P heterogeneity = .02): High marine ω-3 PUFA intake was associated with a lower risk of MSI-high tumors (comparing ≥0.30g/d with <0.10g/d: multivariable HR = 0.54, 95% CI = 0.35 to 0.83, P linearity = .03) but not MSS tumors (HR = 0.97, 95% CI = 0.78 to 1.20, P linearity = .28). This differential association appeared to be independent of CpG island methylator phenotype and BRAF mutation status. CONCLUSIONS: High marine ω-3 PUFA intake is associated with lower risk of MSI-high CRC but not MSS tumors, suggesting a potential role of ω-3 PUFAs in protection against CRC through DNA mismatch repair. Further research is needed to confirm our findings and elucidate potential underlying mechanisms.
Authors: Mai Yamauchi; Teppei Morikawa; Aya Kuchiba; Yu Imamura; Zhi Rong Qian; Reiko Nishihara; Xiaoyun Liao; Levi Waldron; Yujin Hoshida; Curtis Huttenhower; Andrew T Chan; Edward Giovannucci; Charles Fuchs; Shuji Ogino Journal: Gut Date: 2012-03-17 Impact factor: 23.059
Authors: Y C Huang; J M Jessup; R A Forse; S Flickner; D Pleskow; H T Anastopoulos; V Ritter; G L Blackburn Journal: Lipids Date: 1996-03 Impact factor: 1.880
Authors: Sang-Heon Lee; Dong Kyung Chang; Ajay Goel; C Richard Boland; William Bugbee; David L Boyle; Gary S Firestein Journal: J Immunol Date: 2003-02-15 Impact factor: 5.422
Authors: T Kambara; L A Simms; V L J Whitehall; K J Spring; C V A Wynter; M D Walsh; M A Barker; S Arnold; A McGivern; N Matsubara; N Tanaka; T Higuchi; J Young; J R Jass; B A Leggett Journal: Gut Date: 2004-08 Impact factor: 23.059
Authors: T A Brentnall; D A Crispin; M P Bronner; S P Cherian; M Hueffed; P S Rabinovitch; C E Rubin; R C Haggitt; C R Boland Journal: Cancer Res Date: 1996-03-15 Impact factor: 12.701
Authors: Mingyang Song; Xuehong Zhang; Jeffrey A Meyerhardt; Edward L Giovannucci; Shuji Ogino; Charles S Fuchs; Andrew T Chan Journal: Gut Date: 2016-07-19 Impact factor: 23.059
Authors: Mingyang Song; Fang-Shu Ou; Tyler J Zemla; Mark A Hull; Qian Shi; Paul J Limburg; Steven R Alberts; Frank A Sinicrope; Edward L Giovannucci; Erin L Van Blarigan; Jeffrey A Meyerhardt; Andrew T Chan Journal: Int J Cancer Date: 2019-01-28 Impact factor: 7.396
Authors: Shuji Ogino; Reiko Nishihara; Tyler J VanderWeele; Molin Wang; Akihiro Nishi; Paul Lochhead; Zhi Rong Qian; Xuehong Zhang; Kana Wu; Hongmei Nan; Kazuki Yoshida; Danny A Milner; Andrew T Chan; Alison E Field; Carlos A Camargo; Michelle A Williams; Edward L Giovannucci Journal: Epidemiology Date: 2016-07 Impact factor: 4.822
Authors: Raaj S Mehta; Mingyang Song; Reiko Nishihara; David A Drew; Kana Wu; Zhi Rong Qian; Teresa T Fung; Tsuyoshi Hamada; Yohei Masugi; Annacarolina da Silva; Yan Shi; Wanwan Li; Mancang Gu; Walter C Willett; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino; Andrew T Chan Journal: Gastroenterology Date: 2017-02-27 Impact factor: 22.682
Authors: Mingyang Song; Reiko Nishihara; Yin Cao; Eunyoung Chun; Zhi Rong Qian; Kosuke Mima; Kentaro Inamura; Yohei Masugi; Jonathan A Nowak; Katsuhiko Nosho; Kana Wu; Molin Wang; Edward Giovannucci; Wendy S Garrett; Charles S Fuchs; Shuji Ogino; Andrew T Chan Journal: JAMA Oncol Date: 2016-09-01 Impact factor: 31.777
Authors: Akihiro Nishi; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Andy S Tan; Ichiro Kawachi; Shuji Ogino Journal: Expert Rev Mol Diagn Date: 2015-12-04 Impact factor: 5.225